Multigene-engineered fibroblast-derived biomimetic vesicles for cancer multimodal targeting and immune reprogramming
Year: 2026
Type: article
Abstract: Despite advances of biomimetic vesicles in cancer therapy, clinical challenges such as biosafety, scalability, and therapeutic efficacy remain significant hurdles. To address these limitations, we reveal the critical tumor-homing motifs of cancer cell membrane vesicles: a synergistic "chemotactic recruitment-adhesion anchoring" cascade effect, especially chemokine axes (e.g., CXCL12/CXCR4) and integrins (e.g., αVβ3). In this study, we identify autologous fibroblasts as an ideal "chassis" cell for engineering biomimetic carriers. Using this platform, we construct multigene-engineered fibroblast-derived nanovesicles (X-Fb-MNVs) coexpressing critical chemokine receptor CXCR4 and adhesion ligand iRGD, as well as PD-1 and CD47 protein, which achieved robust and broad-spectrum tumor targeting across breast, liver, pancreatic, and colon cancer PDX models. Significantly, CD47-modified X-Fb-MNVs reduced hepatic accumulation and phagocytic clearance, thereby minimizing off-target effects in vivo and improving tumor targeting efficiency. By loading diABZI STING agonist into X-Fb-MNVs with overexpressed PD-1, our system activates both T cell and innate immunity, reversing ICB resistance and achieving 83.3% survival with no tumor recurrence and long-term immune surveillance over 90 d, whereas no mice survived with free diABZI treatment. By merging multimodal targeting, immune reprogramming, and scalable production into a single platform, X-Fb-MNVs represent a remarkable biomimetic system with transformative potential for a wide-spectrum cancer immunotherapy.
Language: English
Subfield: Biomaterials
Field: Materials Science
Domain: Physical Sciences
Open Access status: hybrid
Awards: G3427901029, G3941469939, G6890937400
OpenAlex ID: W7235677714
